Ardelyx, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ARDX Nasdaq 2834 www.ardelyx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ardelyx, Inc.

Should You Buy Ardelyx (ARDX)? - May 30th, 2026 9:18 am
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 - May 19th, 2026 6:01 am
Ardelyx (ARDX) Is Up 10.3% After Long-Term XPHOZAH Safety Data In Dialysis Patients - What's Changed - May 9th, 2026 9:11 am
Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue Guidance - May 7th, 2026 9:25 am
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings - May 7th, 2026 6:01 am
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report - May 2nd, 2026 7:16 am
Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments - May 1st, 2026 1:19 am
Ardelyx, Inc. Q1 2026 Earnings Call Summary - Apr 30th, 2026 6:15 pm
Ardelyx (ARDX) Q1 2026 Earnings Transcript - Apr 30th, 2026 5:32 pm
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates - Apr 30th, 2026 4:25 pm
Ardelyx Q1 Earnings Call Highlights - Apr 30th, 2026 4:16 pm
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics - Apr 30th, 2026 4:00 pm
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update - Apr 30th, 2026 2:01 pm
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings - Apr 27th, 2026 6:01 am
Is Ardelyx (ARDX) Offering Value After Recent Share Price Swings And DCF Estimate Gap - Apr 25th, 2026 2:03 am
Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know - Apr 23rd, 2026 8:00 am
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 - Apr 23rd, 2026 6:01 am
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer - Apr 20th, 2026 6:00 am
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 - Apr 16th, 2026 6:01 am
Global Movement Takes Center Stage as "Champions Raise Awareness" for World IBS Day 2026 - Apr 14th, 2026 6:38 am